Skip to Content

Siliq FDA Approval History

FDA Approved: Yes (First approved February 15, 2017)
Brand name: Siliq
Generic name: brodalumab
Dosage form: Injection
Company: Bausch Health Companies Inc.
Treatment for: Plaque Psoriasis

Siliq (brodalumab) is a human anti-interleukin-17-receptor monoclonal antibody for the treatment of plaque psoriasis.

Development Timeline for Siliq

DateArticle
Feb 15, 2017Approval FDA Approves Siliq (brodalumab) for Plaque Psoriasis
Jul 19, 2016FDA Advisory Committee Recommends Approval Of Brodalumab For Treatment Of Moderate-To-Severe Plaque Psoriasis
Jan 26, 2016Valeant Announces FDA Acceptance of BLA Submission for Brodalumab in Moderate-to-Severe Plaque Psoriasis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.